Professor Farzin Farzaneh
King’s College London
Professor of Molecular Medicine, Director of Cell and Gene Therapy
Farzin Farzaneh D.Phil., FRCPath., FRSB
Professor of Molecular Medicine, and Director of Cell and Gene Therapy – King’s.
Consultant in Specialist Medicine, King’s College Hospital
Farzin Farzaneh holds the Chair of Molecular Medicine at King’s College London. He has published over 250 research articles with an average citation of over 30, and an Impact Factor of 47. He has run a licensed GMP facility at King’s College London, since 2001, for the production of cell and gene therapy based investigational medicinal products. Farzin has extensive industrial and academic collaborations, including research council, charitable and pharmaceutical sponsorships of over £25M. He is appointed by the Commission on Human Medicines, as a member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group since 2016. He is the recipient of 2016 Distinguished Scientist Award of the US Society for Experimental Biology & Medicine.
Advanced Therapy Medicinal Products (ATMPs) for achievement of deeper and longer lasting immune mediated cancer remission
Cell and gene based therapy of cancer is making major improvements to the treatment of cancer. The development of new strategies for the development of chimeric antigen receptor T cells, genetically modified cancer cell vaccines and therapeutic cancer vaccines for the specific induction of cellular immunity will be described.
EVEN MORE SEMINARS
Khurum Khan Royal Marsden NHS Foundation Trust
Biomarkers of response and/or resistance to targeted therapies in refractory mCRC
Dr Sileida Oliveros GenesisCare
Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment
Jamie Rae Throat Cancer Foundation
The Throat Cancer Foundation; how we changed a government’s mind
James Flanagan Imperial College London
Epigenetic biomarkers for platinum response in ovarian cancer
Bertil RR Persson Scandinavian ChemoTech AB. Sweden
Dynamic-ElectroEnhanced Chemotherapy brings relief to patients with large tumour burden